問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Pediatrics

更新時間:2024-06-07

王建得WANG, JIAAN-DER
  • Principal Investigator
  • Clinical Trial Experience (year)
  • wangjiaander@gmail.com

篩選

List

44Cases

2021-12-01 - 2025-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2021-11-17 - 2030-07-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-11-15 - 2028-11-26

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-09-01 - 2027-12-31

Phase III

Active
Phase 3, open label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)
  • Condition/Disease

    The study compared the differences between the trial drug before and after infusion, and evaluated the non-inferiority of the annual average bleeding rate (ABR) of total bleeding events (treatment-free and treatment-free) from week 12 to month 15 compared with standard of care (SOC) FIX prophylactic alternative therapy.

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2020-08-15 - 2023-11-23

Phase III

Completed
An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis
  • Condition/Disease

    (Coagulation Factor Activity <1%) Hemophilia A or B

  • Test Drug

    PF-06741086

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2026-03-15 - 2040-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2022-07-01 - 2028-12-31

Others

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-05-30 - 2027-07-12

Phase III

Active
SYNOVIIIUS: Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients with Hemophilia A
  • Condition/Disease

    Hemophilia A

  • Test Drug

    Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection Lyophilized powder for injection

Participate Sites
3Sites

Recruiting3Sites

2019-10-30 - 2026-11-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5